Print Page | Close Window

Corporate Profile

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Recent Press Releases

October 24, 2016 - 6:24 a.m.
Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based RegimensPrinter Friendly Version 
October 20, 2016 - 10:08 a.m.
Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected PatientsPrinter Friendly Version 

Upcoming Events

Tuesday, November 1, 2016 4:30 p.m. ET
Third Quarter 2016 Gilead Sciences Earnings Conference Call
Monday, November 7, 2016
Credit Suisse 25th Annual Healthcare Conference
LocationScottsdale, AZ
Friday, November 11, 2016 through Tuesday, November 15, 2016
AASLD: The Liver Meeting 2016
LocationBoston, MA

Most Viewed Links

Updated 10/14/16
1.SEC Filings
3.Annual Reports
4.Fundamentals - Snapshot
5.Stock Information
* Data collected 10/06/16 - 10/13/16

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.